# Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients

Source: https://onco.cc/trials/nct04655092/  
OnCo record `nct04655092` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Ropeginterferon alfa-2b in myeloproliferative neoplasms, run by PharmaEssentia Japan K.K., now recruiting.

## Summary

Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients is a phase 3 interventional study registered as NCT04655092 by PharmaEssentia Japan K.K., with 67 participants planned, started 2021-01-19 and due to reach its primary completion in 2026-06-30. Interventions recorded: P1101 (Ropeginterferon alfa-2b).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04655092
- Phase: 3
- Setting: Extension Study of P1101 in Japanese Patients Who Have Completed Phase 2 Single Arm Study in Polycythemia Vera (PV) Patients (Study A19-201) or Phase 3 Study in Essential Thrombocythemia (ET) Patients (Study P1101 ET)
- Sponsor: PharmaEssentia Japan K.K.
- Enrolled: 67

## Sources

- ClinicalTrials.gov NCT04655092: https://clinicaltrials.gov/study/NCT04655092

## Connected records

- cancers: [Myeloproliferative neoplasms (PV, ET, myelofibrosis)](https://onco.cc/cancers/myeloproliferative-neoplasms/)
- drugs: [Ropeginterferon alfa-2b](https://onco.cc/drugs/ropeginterferon-alfa-2b/)

---
JSON: https://onco.cc/api/v1/entities/nct04655092.json